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ABSTRACT
Tectonic family member 2 (TCTN2) encodes a transmembrane protein that 
belongs to the tectonic family, which is involved in ciliary functions. Previous studies 
have demonstrated the role of tectonics in regulating a variety of signaling pathways 
at the transition zone of cilia. However, the role of tectonics in cancer is still unclear. 
Here we identify that TCTN2 is overexpressed in colorectal, lung and ovary cancers. 
We show that different cancer cell lines express the protein that localizes at the 
plasma membrane, facing the intracellular milieu. TCTN2 over-expression in cancer 
cells resulted in an increased ability to form colonies in an anchorage independent 
way. On the other hand, downregulation of TCTN2 using targeted epigenetic editing 
in cancer cells significantly reduced colony formation, cell invasiveness, increased 
apoptosis and impaired assembly of primary cilia. Taken together, our results indicate 
that TCTN2 acts as an oncogene, making it an interesting cancer-associated protein 
and a potential candidate for therapeutic applications.
INTRODUCTION
Cilia are microtubule-based organelles extending 
from the cell surface, which play a pivotal role in 
eukaryotic biology. Primary (non-motile) cilia have an 
important mechanical and chemical sensory role since they 
regulate several signal transduction pathways, including 
the Wnt, Hedgehog (Hh), Platelet-Derived Growth Factor 
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Receptor alpha (PDGFRα) and mTOR signaling systems 
[1–7]. Primary cilia sense a wide variety of extracellular 
signals to control decisions regarding development, 
proliferation, differentiation and tissue maintenance. 
Impairment of ciliary function results in a number of 
diseases, known as ciliopathies, such as polycystic 
kidney disease (PKD), Nephronophthisis (NPHP), 
Alström syndrome (ALS), Bardet-Biedl syndrome (BBS), 
Joubert syndrome (JBTS), Meckel-Grüber syndrome 
(MKS) and others [8–10]. In line with the role of cilia in 
several cellular functions and signaling pathways, recent 
studies have also highlighted the importance of cilia in 
the development of cancer. Alteration or loss of primary 
cilia has been correlated with cellular transformation. 
Accumulating evidences indicate that cancer cells 
lacking cilia show a reduction or modification in their 
response to extracellular signals that regulate growth and 
differentiation [11–13]. Indeed, a number of critical cell 
signaling and adhesion molecules are clustered in the 
cilium, and require an intact cilium for normal function 
[3, 5, 14]. These include components of the Shh and Wnt 
signaling pathways, whose activation/inactivation has 
been linked to several types of cancer [15]. Effectively, 
ciliated tumors may have either active Hh or Wnt [12, 16, 
17]. On the other hand, disruption of sensory cilia leads 
to inhibition of tumorigenesis, due to inactivation of Hh 
signaling [13, 18].
Within ciliary protein components, there are 
members of the tectonic family (TCTN1, TCTN2, 
TCTN3) that have been identified as important regulators 
of Hh pathway [19, 20]. Mutations of the tectonic proteins 
are associated to ciliary dysfunction that underlies 
several ciliopathies [10, 21]. Tectonics (TCTNs) form 
complexes with proteins that localizes to the ciliary 
transition zone, where they regulate ciliogenesis and 
ciliary membrane composition in a tissue-dependent 
manner [22]. Concerning the role of TCTNs in cancers, 
available information are limited to TCTN1, which has 
been described as an important regulator of proliferation 
and migration of cancer cells [23]. TCTN1 is also 
important to maintain active Hh signaling during neural 
tube development [19]. Tectonics could exert their 
activity in signal transduction through their functional 
interaction with MKS1, a ciliary basal body protein that 
has a potential role in regulating both Wnt signaling, 
which regulates cell proliferation and its alteration causes 
different diseases, including cancer. MKS1 also acts 
upstream of Patched and influences Shh signaling. Loss 
of MKS1 causes a reduction in high-level Shh signaling. 
In various types of tumor, mutation in Hedgehog signaling 
leads to hypoplasia [24], thereby inhibition of the Shh, 
one of the major components of the pathway, has been 
identified as a possible therapeutic strategy for gastric 
cancer [25].
In this study, we report for the first time the presence 
of TCTN2 in a significant percentage of colorectal cancer 
(CRC) as well as lung and ovary cancers. Moreover we 
find the protein to be expressed at the level of the plasma 
membrane in cancer cell lines of different origins. By 
using a gene-targeting approach, we also show that 
inhibition of TCTN2 expression significantly affects cell 
invasiveness, clonal growth, cilia formation, and increases 
cell apoptosis. Conversely, TCTN2 over-expression 
increases the clonogenic property of cancer cells. All 
these data together suggest that TCTN2 could be a novel 
oncogene and that it could be exploited as potential 
candidate for therapeutic applications.
RESULTS
TCTN2 is over-expressed in human cancers
In our recent research, we described the use of 
the YOMICS® murine polyclonal antibody library 
(http://www.yomics.com) to discover tumor markers by 
IHC analysis [26, 27]. In essence, this antibody library 
includes antibodies raised against 1287 secreted or 
membrane-associated human proteins, most of which are 
still marginally characterized. The entire antibody library 
is currently used to screen Tissue microarrays (TMAs) 
carrying clinical samples from major human cancers. 
During the screening of this antibody library on TMAs 
containing cancerous and normal formalin-fixed paraffin-
embedded (FFPE) samples from breast, colorectum, 
lung, ovary and prostate (5 tumor and 5 matched normal 
samples, in duplicate), we found that a polyclonal antibody 
(pAb291-YOM) raised against a recombinant domain of 
TCTN2, encompassing the protein region from amino acid 
170 to amino acid 443 (rTCTN2), specifically detected the 
expression of its target protein in cancer samples of colon 
(3/5), lung (2/5) and ovary cancers (2/5) whereas it gave 
a negligible staining in the corresponding normal tissues 
(Supplementary Figure 1). Based on this initial indication, 
a mouse monoclonal antibody (TCTN2 mAb) was 
generated in-house against the same domain (rTCTN2) 
utilized to generate the polyclonal sera and used to 
analyze approximately 50 samples from colorectum, lung 
and ovary cancers, and 5 samples from matched normal 
tissues, in duplicate. In general the monoclonal antibody 
staining was cytoplasmic, though in some samples it also 
decorated the plasma membrane (Figure 1A). This mAb 
mainly detected TCTN2 in colorectum cancer (63.8%; P 
value <0.0001), as compared to lung (18%), and ovary 
(16%) cancer samples, with marginal or negative staining 
in tested normal samples. An IHC scoring system based 
on a combined evaluation of the intensity of mAb staining 
(from 1 to 3) multiplied by the percentage of positive 
cancer cells (from 1 to 100), showed that a higher fraction 
of samples with strong or moderate staining (IHC score 
>100) in colorectal (30%) vs lung (10%) and ovary (0%) 
cancers, suggesting a highest expression of TCTN2 in 
colorectal cancer (Table 1). TCTN2 association with colon 
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Figure 1: TCTN2 is overexpressed in primary tumors of colon lung and ovary. (A) TCTN2 is overexpressed in tumor 
samples and localizes at the cell membrane. Cancerous and matched normal samples from colon, lung and ovary were stained with the 
anti-TCTN2 monoclonal antibody, arrayed in parallel on the same TMA slides and analyzed simultaneously. (B) Specific recognition of 
TCTN2 antibodies - TCTN2 expressed in mammalian cells is a glycosylated protein. Western blot on total protein extracts from HeLa cells 
transfected with the empty plasmid or full length TCTN2, or recombinant TCTN2 domain (amino acids 171-444) expressed in E. coli, 
using the polyclonal (pAb291-YOM, left panel) and monoclonal antibody (anti-TCTN2 mAb, right panel). The recognition of the mAb anti 
TCTN2 was also assessed after treatment with Peptide-N-Glycosidase F (PNGaseF).
Table 1: IHC staining of colon, lung and ovary samples using the anti-TCTN2 mAb
IHC score > 0 > 100











Ovary cancer (%) 8/50 (16) 0/50 (0)
Asterisk represents the statistical significance of Fisher’s exact test. P value < 0.0001; ***; P value < 0.05. *
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cancer was also confirmed by using Receiving Operator 
Characteristic curves analysis (Supplementary Figure 2).
To further validate these findings and to investigate 
the role that TCTN2 might have during cancer progression, 
the protein expression was further assessed on an 
independent collection of colon cancer cases (163 samples) 
selected on the basis of the availability of relevant clinical 
and molecular data (Supplementary Table 1). The TCTN2 
protein was detected in 93% of the cases (21.5% with a 
strong or moderate staining), with no remarkable differences 
in detection frequency among tumor staging and grading 
histological criteria. (Table 2). The fraction of samples with 
moderate/strong TCTN2 staining moderately decreases in 
stage 4 and grade 3 cancers than in less advanced and low 
grade cancers (Table 2). All these data indicate that TCTN2 
is associated with human cancers among which the highest 
expression level was found in colon cancer.
The specificity of the monoclonal and polyclonal 
antibodies used for IHC was verified by Western blot on HeLa 
cells transfected with full-length TCTN2. TCTN2 is predicted 
to encode a protein of 77 kDa with four potential glycosylation 
sites. As shown in Figure 1B, both polyclonal and monoclonal 
antibodies specifically detected a main band around 100 kDa in 
TCTN2-transfected HeLa cells, which was not visible in HeLa 
cells transfected with the “empty” plasmid. However, when 
the protein extracts were treated with PNGase F, the immune-
reactive band shifted to around 80 kDa thus confirming the 
predicted molecular weight and glycosylation.
TCTN2 protein is expressed in cancer cell lines 
and mainly localized on the intracellular side of 
the plasma membrane
To better characterize TCTN2 protein expression 
and localization in tumors we selected a panel of breast, 
lung, colon, and ovary tumor cell lines. In these cell lines 
we assessed TCTN2 expression by Western blot. Immuno-
reactive bands around 100 kDa, were detected in MCF7, 
H226, HOP92, HCT15, HT29, Colo205, OVCAR8 and 
SCOV3 cell lines while the same bands were very faint or 
Table 2: TCTN2 frequency in CRC using an anti-TCTN2 mAb
Clinical Parameter Status/Score Total Positive (%) Medium-Strong Positive (%)
Histology adenocarcinoma 134/141 (95) 34/141 (24)
1/22 (4) ]*mucinous 19/22 (86)
Stage 1 27/27 (100) 8/27 (30)
2 43/47 (91) 10/47 (21)
3 52/53 (98) 13/53 (24)
4/32 (12) ]*4 27/32 (84)
pT 1 10/10 (100) 1/10 (10)
2 30/31 (97) 8/31 (26)
3 90/95 (95) 24/95 (25)
4 24/28 (86) 2/28 (7)
pN 0 74/79 (94) 19/79 (24)
1 45/47 (96) 11/47 (23)
2 29/32 (91) 5/32 (16)
Grading 1&2 112/119 (94) 30/119 (25)
3 41/44 (93) 5/44 (11)
Metastasis No 94/99 (95) 25/99 (25)
Yes 62/67 (92) 10/67 (15)
Vascular Invasion No 41/44 (93) 9/44 (20)
Yes 111/118 (94) 26/118 (22)
Sex female 81/87 (93) 22/87 (25)
male 75/79 (95) 13/79 (16)
Fisher’s exact test P value < 0.05 is represented by asterisk *
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negative in SKBR3 (Figure 2A). These bands might likely 
represent different glycosylation states of the protein. 
To further evaluate the mAb specificity for the target 
we used four different TCTN2-specific siRNAs (10 nM) 
to silence TCTN2 expression in HOP92, OVCAR8 and 
HCT15 cells. All cell lines showed a significant reduction 
of TCTN2, both at transcript and protein levels, as verified 
by q-RT-PCR and Western blot with all tested siRNA, 
compared to cells treated with an irrelevant siRNA (Figure 
2B). Afterwards, we assessed TCTN2 localization by 
confocal microscopy in HCT15, HOP92 and HT29 cancer 
cell lines, by permeabilizing or not the cell membrane with 
the detergent BRJ96. TCTN2 was detected at the level of 
the plasma membrane only in permeabilized cells whereas 
it was undetectable without detergent treatment (Figure 
2C) Similar data were obtained in MCF7 and OVCAR8 
cell lines (data not shown). This result indicates that the 
protein is not accessible to the antibody on the cell surface 
without permeabilization, thereby it is likely localized on 
the intracellular side of plasma membrane.
Downregulation of TCTN2 by epigenetic editing
To investigate the alteration of cell growth and 
viability caused by loss of TCTN2 expression we 
developed epigenetic editing methods relying on the 
repression of its endogenous genomic locus and therefore 
able to perform a more sustained manner of silencing. To 
identify the best region to target within the promoter area, 
we used the CRISPR-dCas system to test two different 
sgRNAs recognizing regions: one mapping in the close 
proximity of the predicted transcription start site (TSS) 
and one 234 nucleotides upstream of the TSS (referred 
to as region A and B, respectively) (Figure 3A). In four 
cancer cell lines from different tissue origin (MCF7, 
breast cancer; SKOV3, ovary cancer; HOP92, lung 
cancer; HT29, colon cancer), we observed that the region 
A, the one located closer to the transcription start site, 
was better to achieve gene downregulation, irrespective 
of the effector domain used (Figure 3B). To further 
confirm our findings, we designed two DNA binding 
domain Zinc finger proteins to bind the same two regions 
of the promoter (referred as ZFA and ZFB, respectively), 
fused to the transcriptional repressor Super Krab Domain 
(SKD). The same four cancer cell lines were transduced 
with retroviral vectors expressing ZFA, ZFA-SKD, or ZFB-
SKD and 4 days later RNA expression level was assessed 
by q-RT-PCR and compared with cells treated with the 
empty vector, which served as negative control. ZFA 
-SKD transduced cells showed a significant reduction of 
transcription (ranging from 2 to 10-fold) in the four cell 
lines, whereas TCTN2 transcription levels in ZFB-SKD 
expressing and control cells was similar (Figure 3C). ZFA 
alone also affected mRNA expression (from up to 2-fold) 
in HOP92 and HT29, although not significantly.
We then assessed whether enforced TCTN2 
downregulation influences viability and growth of cancer 
cells. We first analyzed the apoptotic phenotype of the four 
cancer cell lines transduced with ZFA-SKD, ZFB-SKD, 
or ZFA using the DilC1 staining assay [28], as compared 
to controls treated with the empty plasmid or untreated. 
Transduction with ZFA-SKD significantly increased 
apoptosis in HT-29 cells (approximately 3 fold) (Figure 
3D). Interestingly in the same cells, also transduction with 
ZFA alone increased the apoptotic phenotype, although 
it was not statistically significant. No significant effects 
on apoptosis were observed in the other cell lines and the 
expression of ZFB-SKD caused no effect in either cell 
line. Afterwards, we assessed cell proliferation using the 
PrestoBlue assay. A marginal reduction (approximately 
20%) was observed in the proliferation of HT29 cells 
transduced with ZFA-SKD and ZFA constructs while there 
was no significant effect on proliferation of the HT29 cells 
transduced with the ZFB-SKD construct when compared to 
the original cell line (data not shown).
TCTN2 modulation influences cell invasiveness 
and anchorage-independent growth of cancer cells
We then investigated the anchorage-independent 
growth phenotype of the transduced cell lines by the soft 
agar assay, one of the most stringent test commonly used 
to assess malignant transformation in cells. All cell lines 
expressing ZFA-SKD showed a reduced number of colonies 
in the soft agar assay (ranging from 2 to 5 fold). Also 
in this assay, cells treated to express ZFA alone showed 
a reduced capacity to produce colonies (Figure 3E–3F). 
The observed phenotypic effects were further confirmed 
by creating stable cell lines able to downregulate TCTN2 
from the endogenous genomic locus with an inducible 
system. To this aim, the HT-29 cell line was transduced 
with a doxycycline (Dox) inducible system with different 
DNA binding domains coupled to either a transcriptional 
repressor (SKD) or an epigenetic enzyme (JARID1A) that 
demethylates H3K4me3. After adding 100 µg/ml of Dox 
for 72 hours to the cells, an efficient downregulation of 
TCTN2 in stable HT-29 cells was achieved using ZFA, 
ZFA-SKD and ZFA-JARID, whereas it was unaltered by 
ZFB-SKD and ZFB-JARID constructs (Figure 4A). TCTN2 
was also in part downregulated before Dox addition, likely 
due to a leaky expression of ZFA-SKD. Despite potential 
leakiness, sub-culturing cells for 7 additional days without 
Dox reversed the TCTN2 downregulation caused by either 
ZFA constructs.
The influence of TCTN2 downregulation on tumor 
aggressiveness was assessed in HT-29 cells using in vitro 
assays measuring features like cell invasiveness and 
clonal growth in anchorage independent conditions. In 
the Boyden assay, also useful to measure cell migration, 
the cells transduced with the ZFA-SKD construct showed 
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Figure 2: TCTN2 is expressed in cancer cell lines and localizes in the inner side of plasma membrane. (A) Total proteins 
were extracted from breast (SKBR3 and MCF7), lung (H226 and HOP92), colon (HCT15, HT29 and Colo205) and ovarian (SKOV3 
and OVCAR8) cancer cell lines. Proteins were resolved by SDS-polyacrylamide gel electrophoresis and analyzed by Western blot with 
anti-TCTN2 monoclonal antibody. Anti-β-Actin monoclonal antibody was used as a loading control. (B) TCTN2 was silenced in HOP92, 
OVCAR8 and HCT15 cancer cell lines with four commercially available (QIAGEN) TCTN2-specific siRNAs at 10 nM concentration or 
irrelevant siRNA (AllStars Negative Control siRNA, QIAGEN) using the Hi-Perfect transfection reagent (QIAGEN). TCTN2 expression 
was assayed 48 hours later by Western blot. Anti-β-Actin monoclonal antibody was used as a loading control. (C) TCTN2 localizes in the 
inner side of plasma membrane in cancer cells lines. HCT15, HOP92 and HT29 cells were analyzed by confocal microscopy. Cells were 
incubated with the anti-TCTN2 monoclonal antibody, with (lower panels) or without (upper panels) permeabilization pre-treatment with 
0.01% BriJ96®. Cells were subsequently stained with Alexafluor 488-labeled goat anti-mouse antibodies to detect TCTN2 (green) and 
DAPI to visualize nuclei (blue).
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Figure 3: TCTN2 downregulation, by different platforms, alters growth phenotypes in four cell lines. (A) Representation 
of TCTN2 gene promoter and first exon, transcription start site (TSS); A and B mark the region targeted. (B) TCTN2 mRNA downregulation 
using CRISPR-dCas9 sgRNA A and B regions alone. (C) TCTN2 mRNA downregulation using ZF A and B regions fused to a transcriptional 
repressor (SKD). (D) Apoptosis was measured using the 1, 1′,3,3,3′,3′-Hexamethylindodicarbocyanine iodide (DilC) assay in cells treated 
with different ZFs after TCTN2 downregulation. (E) Colony-forming assay in cells after TCTN2 downregulation. (F) Visual representation 
of the colony-forming assay from HT-29 cells. Data represent the mean value of two independent experiments, run in triplicate, and are 
shown as mean ± s.e.m. Statistical significance was assessed by non paired two-tailed Student’s t-test (*P<0.05, **P<0.01, ***P<0.001).
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Figure 4: TCTN2 act as an oncogene: evidences collected by means of epigenetic editing and overexpression. (A) Stable 
inducible HT-29 cells were generated and TCTN2 downregulation was addressed over time, after short-term induction of ZFP fusions. 
(B) Boyden invasiveness chamber assay in cells after TCTN2 downregulation induced by Dox addition. Cells migrated towards the lower 
surface of the chamber filters were fixed and counted after Diff-Quick staining. Images of the visual counting of each sample are reported 
below the graphs. (C) Colony forming assay in cells after TCTN2 downregulation induced by Dox. Lower panel: visual representation 
of the colony-forming assay from HT-29 cells without and with Dox treatment. (D) Anchorage-independent growth of HCT15 cells after 
transfection with a plasmid encoding full-length TCTN2. Data represent the mean value of two independent experiments, run in triplicate, 
and are shown as mean ± s.e.m Statistical significance was assessed by nonpaired two-tailed Student’s t-test, (*P<0.05, **P<0.01, ***P<0.001). 
(E-H) Confocal microscopy evaluation of cilia formation in Dox-treated HT-29 and ZFP fusions transduced cells. Cilia were labeled for 
alpha-tubulin acetylation (green) and nuclei were stained with DAPI (blue). Representative images at lower (E, top row; scale bar: 50 μm) 
and higher (E, bottom row; scale bar: 10 μm) magnification are shown for HT-29 cells and ZFP fusions transduced cells, as specified on top 
of the panels. White arrow-heads point to labeled cilia. Image analysis was conducted on n=2 independent biological replicates, accounting 
for n=650 cells over at least 8 FOVs/condition. Results in HT-29 cells and ZFP fusions transduced cells, were respectively plotted as 
number of surface cilia/area (F panel), surface fluorescence intensity/number of cells (G panel), and cilia density (MFI/area) (H panel). 
Statistical significance was attested using ANOVA test plus Dunnet comparisons (*P<0.05, **P<0.01, ***P<0.001).
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a marked reduction of invasiveness (approximately 3 fold) 
after Dox treatment (Figure 4B). Cells modified with ZFA 
also showed reduced invasive properties, as compared to 
cells transduced with the ZFB-SKD or untreated HT-29 
cells.
The soft agar assay was used to assess clonal 
growth. After Dox treatment, HT29 cells transduced with 
both the ZFA constructs showed a marked decrease in the 
clonogenic phenotype (up to 1 log reduction in the number 
of colonies, compared to cells cultured without Dox) while 
cells transduced with the ZFB-SKD construct were not 
affected by the Dox treatment (Figure 4C).
We then sought to confirm the oncogenic potential 
of TCTN2 by over-expressing it in human cells and 
determining clonal growth. HCT15 cells were transiently 
transfected with a TCTN2-encoding plasmid and the 
resulting phenotype was monitored for 7 days in the soft 
agar assay, by assessing the number of cell colonies, as 
compared to cells transfected with the empty plasmid. As 
shown in Figure 4D, TCTN2 over-expression resulted in 
an increase of the number of HCT15 cells able to form 
colonies (approximately 2 fold), as compared to control 
cells transfected with the empty vector.
TCTN2 downregulation impairs the formation of 
primary cilia
Given the peculiar cellular localization assigned to 
TCTN2, it was very intriguing to assess if TCTN2 loss 
of expression could have also an influence in cilium 
formation. To this aim we monitored the presence of 
acetylated α-tubulin, which is essential for the assembly 
of primary cilia. After 72 h of Dox treatment, HT-29 
cells and the relative ZF-transduced cell lines were 
permeabilized, stained with an anti-acetylated α-tubulin 
antibody and analyzed by confocal microscopy. As shown 
in Figure 4E-4H a marked impairment of cilia formation 
was observed in the ZFA-SKD transduced cells compared 
to untreated HT-29 cells in terms of both numbers of 
surface cilia (14±3/mm2 vs. 73±15/mm2, P<0.01) and 
density of acetylated α-tubulin associated to the cilium 
quantified as cilia mean fluorescence intensity relative 
to the occupied area (47±4 vs. 171±6, P<0.001). Similar 
effects were observed when comparing ZFA-SKD to ZFB-
SKD modified cells (P<0.05 for surface cilia number/area; 
P<0.001 for cilia density). Again cells treated to express 
the ZFA construct also showed a visible reduction of both 
surface cilia and cilia density, compared to untreated cells 
(P<0.05) and to ZFB -SKD modified cells (P<0.05 and 
P<0.001, respectively).
DISCUSSION
TCTN1, TCTN2 and TCTN3 (TCTNs) proteins 
are emerging as critical ciliary components that form 
high affinity complexes in the cilium transitional zone. 
They could modulate signal transduction of Hh and 
Wnt pathways through their functional interaction with 
MKS1 [20]. While the relevance of Wnt and Hh in cancer 
is well documented, the role of TCTNs has been so far 
marginally addressed. The only member of this family that 
has been reported to act as an important player in human 
cancers is TCTN1 [29]. Indeed, it is expressed in human 
glioma, pancreas and prostate cancer cell lines. Moreover, 
in human glioblastoma (GBM) TCTN1 overexpression 
predicts poor clinical outcome for patients [30].
The present study significantly contributes to 
the current knowledge on TCTN2, by providing robust 
experimental evidence that it is associated with human 
cancer. By an IHC study we discovered that the protein 
is highly expressed in colon, lung, and ovary cancers, 
among which the highest expression level (based on 
samples with IHC score >100) was found in colon cancer. 
The presence of TCTN2 in human cancer is also supported 
by transcription profile data available in the Oncomine 
database (https://www.oncomine.org) reporting that this 
gene is upregulated in specific cancer subsets among 
colorectal cancer, non small cell lung cancer, gastric 
cancer, sarcoma, lymphoma and others.
We found that TCTN2 is expressed in cell lines 
derived from different cancers, and it is associated to 
the plasma membrane, but not protruding towards the 
extracellular side. Notwithstanding our IHC data clearly 
showed a main TCTN2 association with colon cancer, we 
did not found any remarkable peak of TCTN2 expression 
in colon cell lines vs the other tested cancer cell lines. 
It would be interesting to investigate whether TCTN2 
expression in colon cancer could increase in response to 
specific signal or environmental conditions.
In this study we demonstrated that TCTN2 plays 
an important role in the growth of cancer cells by using 
targeted epigenetic editing. Indeed, loss of TCTN2 
reduced the ability of four cancer cell lines to form 
colonies independently of a solid surface and, remarkably, 
it increased cell apoptosis; it also influences cell viability, 
though to a moderate extent. Moreover, transient TCTN2 
over-expression in HCT15 cells elicited by conventional 
cDNA transfection substantially increased the colony-
forming phenotype. Additionally, we found that loss 
of TCTN2 caused by transient silencing significantly 
affects cell invasiveness, suggesting a role for the protein 
in the development of the tumor cell ability to penetrate 
the surrounding tissues leading to the formation of 
metastasis. Further in vivo investigation are needed to 
confirm the tumorigenicity and metastasis formation 
capacity of tumor cell lines with intact or downmodulated 
TCNT2 expression. Interestingly, we found that TCTN2 
is expressed in the plasma membrane of cancer cell lines 
probably associated to the cilium. Indeed we observed 
that loss of TCTN2 expression significantly reduces 
cilia formation in HT-29 cells. An interesting aspect 
to be elucidated is whether the cilium defect caused by 
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loss of TCTN2 expression also contributes to the altered 
migratory/invasive phenotype of colon cancer cells.
Moreover, we hypothesize that the phenotypic 
effects caused by variation of TCTN2 expression could 
be due to a chain signaling reaction mediated by MSK1. 
As described for TCTN1, variation of TCTN2 expression 
could affect the interaction of the TCTN complex with 
MSK1 and influences its expression in the cilia, thereby 
leading to Wnt and Shh signaling transduction that can 
ultimately result in aberrant growth of cancer cells. This 
aspect deserves future studies.
Overall, our study provides additional hints on the 
role of TCTNs proteins in cancer development. Knock 
down approaches proved that TCTN1 is essential for 
cancer cell viability and proliferation, suggesting that its 
dysregulation may play a key role in tumorigenesis [23, 
31, 32]. TCTN2, taking part to a supramolecular functional 
complex with TCTN1, could act in combination with it in 
conferring cellular phenotypes relevant for tumor growth 
and spread to distal sites. Indeed, the capability to grow in 
an anchorage independent way is considered a hallmark 
of carcinogenesis our experimental evidences showing 
that loss of TCTN2 expression significantly reduces such 
phenotypes suggest that it might act as an oncogene. 
Moreover, it would be interesting to test whether, as 
reported for TCTN1 in GMB [30], TCTN2 could represent 
a prognostic factor for TCTN2-over-expressing cancers. 
Finally, our in vitro data also provide the rationale for the 
design of novel TCTN2-targeting drugs. Targeted epigenetic 
editing can eventually serve as a therapeutic approach to 
stably alter gene expression patterns in cells [33, 34].
MATERIALS AND METHODS
Reagents and cell cultures
Unless specified, all reagents were obtained 
from Sigma. His-tagged recombinant TCTN2 domains 
and polyclonal antibodies were generated in E. coli as 
described [26]. Human cells were obtained from the ATCC 
collection and, unless differently stated, cultured under 
ATCC recommended conditions. Cell culture media were 
from BioWhittaker (Walkerville, MD, USA). All cells 
were cultured at 37°C under 5% CO2.
IHC analysis
TMA production and IHC staining were performed 
essentially as previously described [26, 35, 36]. Briefly, 
formalin-fixed, paraffin-embedded tissue blocks of CRC 
resections and normal samples were retrieved from 
the archives of the Institute of Pathology, University 
Hospital Basel and the Institute of Clinical Pathology 
Basel, Switzerland. CRC and normal samples were 
arrayed in parallel on the same TMA slides and analyzed 
simultaneously. One tissue cylinder with a diameter of 0.6 
mm was punched from morphologically representative tissue 
areas, mostly central tumor areas and rather away from the 
infiltrating tumor border. Clinico-pathologic data from the 
corresponding series of cancer cases were obtained from 
archived files. Concerning the scoring of TCTN2 staining, 
slides were screened semi-quantitatively for the percentage 
and the intensity of the signal for TCTN2. At least 100 cells 
were counted for each punch. Intensity of the signal was 
graded semiquantitatively in 4 groups from 0 (no positivity) 
to 3 (strong positivity). A case was considered low positive 
if showed a positive signal between 10% and 33% of cells, 
moderate positive between 33 and 66% and strong positive 
more than 66%. Negative control samples were prepared 
by using an irrelevant isotype control antibody and/or by 
omitting the primary antibody. Ethics approval for this study 
was obtained from the Ethic Committee for Human Research 
of the Basel University Hospital (Ethikkommission Nord-und 
Zentralschweiz, EK 322/13).
Cell transfection
A pcDNA3.1D (Invitrogen) derivative plasmid 
encoding TCTN2 full-length cDNA was generated and 
sequence verified. HeLa or HCT15 cells (400,000/well, 
in 6-well plates) were transfected with 4 micrograms of 
the TCTN2 plasmid or with the empty vector as negative 
control using the Lipofectamine-2000 transfection reagent 
(Invitrogen) following the manufacturer’s protocol.
TCTN2 silencing with siRNA technology
TCTN2 was silenced in HOP92 and OVCAR8 cancer 
cell lines with four commercially available (QIAGEN) 
TCTN2-specific siRNAs at 10 nM concentration (#1- 
SI04153632: TGCATCCGTCCAGTTTATTAA), (#2- 
SI04159183: AAGCCTATAGTTAGACAACCA), 
(#3- SI04200686: TTGGAACTATACCAAGAACGA), 
(#4- SI04220433: TGGCTCGAAATAATACGTGTA), 
or irrelevant siRNA (AllStars Negative Control siRNA, 
QIAGEN) using the Hi-Perfect transfection reagent 
(QIAGEN) following the manufacturer’s protocol. TCTN2 
expression was assayed 48 hours later by real-time q-PCR 
and Western blot with anti-TCTN2 monoclonal antibody. 
Anti-β-Actin monoclonal antibody was used as a loading 
control.
RNA extraction and q-RT-PCR analysis
RNA extraction from cell lines was performed 
using the RNeasy mini kit (QIAGEN) according to 
manufacturer’s protocol and 500 ng of it were reverse 
transcribed using Superscript III Reverse Transcriptase 
(Life Technologies) with oligo-dT. Triplicate cDNA 
samples from each sample (equal to 50 ng RNA/
sample) were subjected to to assess the expression of 
TCTN2 (primers RT2 qPCR Primer Assay for Human 
TCTN2, QIAGEN) using the Quantitect SYBR Green 
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PCR kit (QIAGEN). MAPK or GAPDH (primers RT2 
qPCR Primer Assay for Human MAPK or GAPDH, 
QIAGEN) were used as an internal normalization controls, 
respectively. Data were analyzed with the One-Step Plus 
q-RT-PCR equipment (Applied Biosystems). Fold change 
in mRNA expression above control untreated cells was 
calculated based on the cycle threshold (ΔΔCt) method 
after normalization to MAPK or GAPDH expression.
Electrophoresis and western blot analysis
Cell monolayers were detached with PBS-0.5 mM 
EDTA and lysed with either Triton X-100 or RIPA buffer 
by incubating cell suspensions for 30 min at 4 °C with 
continual rotation prior to removal of the insoluble fraction 
by centrifugation at 10000xg for 30 min at 4 °C. Total 
protein extracts were loaded on SDS-PAGE (2x105 cells/
lane) and expression of target proteins was assessed by 
Western blot analysis using specific antibodies. Western 
blot was performed by separation of the protein extracts on 
pre-cast SDS-PAGE gradient gels (NuPage 4-12% Bis-Tris 
gel, Invitrogen) under reducing conditions, followed by 
electro-transfer to nitrocellulose membranes (Invitrogen) 
according to the manufacturer’s recommendations. The 
membranes were blocked in blocking buffer composed 
of 1x PBS-0.1% Tween 20 (PBST) added with 10% dry 
milk, for 1 h at room temperature, incubated with the 
antibody diluted 1:2500 in blocking buffer containing 1% 
dry milk and washed in PBST-1%. The secondary HRP-
conjugated antibody (goat anti-mouse immunoglobulin/
HRP, Perkin Elmer) was diluted 1:5000 in blocking buffer, 
and chemiluminescence detection was carried out using a 
Chemidoc-IT UVP CCD camera (UVP) and the Western 
LightningTM Cheminulescence Reagent Plus (Perkin 
Elmer), according to the manufacturer’s protocol.
Confocal microscopy analysis of TCTN2 
expression
Cells were plated on glass coverslips. After 48 
h, they were washed with PBS and fixed with 3% 
formaldehyde solution in PBS for 20min at RT. Then, after 
extensive washing in PBS, the cells were permeabilized 
with 0.01% BriJ96® (Fluka) and subsequently incubated 
with the anti-TCTN2 mAb antibody anti-overnight at 4 
°C. Cells were then stained with Alexafluor 488-labeled 
goat anti-mouse antibodies (Molecular Probes). DAPI 
(Molecular Probes) was used to visualize nuclei. The cells 
were mounted with glycerol plastine and observed under 
a laser-scanning confocal microscope (LeicaSP5) and Z 
stacks of fields of cells were acquired from each condition 
using a 63x oil objective (N.A. 1.4). Digital images were 
taken using LAS AF software (Leica).
Engineering ZFPs and plasmid construction
Plasmids containing a mammalian codon-optimized 
dCas9-VP64 activator (pMLM3705) and the single-
chain guide RNA encoding plasmid (pMLM3636) were 
bought from Addgene. An additional multiple cloning 
site was added by replacing the VP64 activator in the 
dCas9-VP64 with a sequence containing a PacI restriction 
site (new plasmid referred to as dCas9-Empty). The 
Super Krab Domain (SKD) was subcloned from pMX-
6ZF-SKD into dCas9-VP64, by using BamHI and XhoI 
enzymes, to replace VP64 with SKD. Two target regions 
of 20 bps of the TCTN2 promoter were selected to design 
gRNAs based on close proximity to the transcription 
start site (TSS) (A: ; B:). Cloning of gRNAs was 
achieved as previously described. Briefly, pairs of DNA 
oligonucleotides encoding 20 nucleotide gRNA targeting 
sequences were annealed together to create double-
stranded DNA fragments with 4-bp overhangs. These 
fragments were ligated into BsmBI-digested plasmid 
pMLM3636. Two target regions of 18 bps of the TCTN2 
promoter close to the gRNA binding sites were selected 
based on high affinity predictions (www.zincfingertools.
org) and the uniqueness of the target sites confirmed 
by a blast on NCBI. Double stranded DNA oligos (BIO 
BASIC, Markham, Canada) coding for the two 6-finger 
ZFPs (ZFA: GCAACAGGGGGCGGGGGG and ZFB: 
GGGGAGGAAGCCGCAGCC minus strand) flanked 
with the restriction site SfiI, were subcloned into the 
pMX-IRES-GFP alone called no effector domain (NED) 
or containing either the gene repressor super krab domain 
(SKD) or epigenetic effector domain JARID1a.
Retroviral transductions
HEK293T cells were co-transfected with the 
retroviral vector pMX-IRES-GFP along with VSV-G 
viral envelope (pMD2.G) and the gag/pol proteins 
(pMDLg/pRRE) using CaPO4. 48 and 72 hours after 
transfection, the viral supernatant was used to transduce 
host cells supplemented with FBS and 5µg/ml polybrene 
(Sigma, St. Louis, MO, USA). Cells were harvested for 
further experiments three days after the last transduction. 
GFP positivity of cells was assessed on a Calibur Flow 
Cytometer (Beckton Dickinson Biosciences).
Generation of stable cell lines
Retroviral particles from pRetroX-Tet-On-
Advanced (pTet-On) (CloneTech, Mountain View, CA) 
were generated using conventional CaPO4 transfection of 
HEK-293T. Virus-containing supernatant was harvested 
48 and 72 hours post-transfection, supplemented with 
FBS and 5µg/ml polybrene, and used to transduce HT-
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29 cells. Two days after transduction, cells were selected 
with 1µg/ml geneticin (Gibco/Invitrogen) for 5 days and 
individual clones were subcultured for testing using the 
pRetroX-Tight-Luc-Pur (CloneTech, Mountain View, 
CA). The clone with the highest expression of luciferase 
after induction was chosen for subsequent use. The 
coding region of the fusion proteins of ZFA and ZFB with 
SKD or JARID1a were subcloned into the expression 
vector pRetroX-Tight-Pur (CloneTech, Mountain View, 
CA) using the BamHI/NotI restriction sites. Retroviral 
transduction of the plasmids was carried out as described 
previously using the stable pTet-On HT-29 cells. Two 
days after transduction cells were selected with 1 µg/ml 
geneticin (Gibco/Invitrogen) for 10 days. Expression of 
the fusion proteins was induced using Doxycycline (Dox, 
100 µg/ml) for 72 hours.
Clonogenic assay
Following transfection or transduction, cells were 
plated in 6-wells plates (2000-4000 cells per well). After 
two weeks, medium was aspirated and colonies were 
stained with Coomassie brilliant blue (Bio-Rad). The 
number of colonies was determined using phase contrast 
microscopy and Image J.
Apoptosis assay
Cell apoptosis was measured using the 1, 
1′,3,3,3′,3′-Hexamethylindodicarbocyanine iodide (DilC) 
assay (Enzo Life Sciences) and the Annexin V-PI assays 
(Sigma) according to the manufacture’s protocol. For the 
DilC assay, following treatment, cells were trypsinized 
and incubated in culture medium supplemented with 
DilC (50 nM) for 15 min at 37°C. After washing with 
PBS, DilC signal was analyzed using FACS Calibur 
(BD Biosciences). The percentage of apoptotic cells 
was determined as the number of viable cells with 
decreased DilC intensity, as reported before [37]. Assays 
were performed in 96w-well plates according to the 
manufacturer’s instruction. Each experiments was carried 
out in triplicate and averaged from at least 3 independent 
experiments.
Cell invasiveness
Cell invasiveness was assessed by the Boyden 
chamber assay. Cells (2000/well) were placed onto 
Matrigel-coated 24-well plates and, after ON incubation 
at 37°C, non-invading cells were removed mechanically 
using cotton swabs, and micro-porous membrane 
containing the invaded cells was fixed in 96% methanol 
and stained with Diff-Quick staining solutions. 
Invasiveness was evaluated by counting the cells that 
migrated towards the lower surface of the filters (10 
randomly chosen fields for each filter). Each experiment 
was carried out in triplicate and averaged from at least 3 
independent experiments.
Cell proliferation
PrestoBlue cell viability reagent (Life Technologies) 
was used to measure cell proliferation. Briefly 6-, 20- and 
60 x103 cells were seeded per well in triplicate in 96-well 
white plates in 90μl medium. Cells were incubated for 
72 h. Then 10μl of PrestoBlue was added to each well. 
Cells were further incubated for 1 h. Cell proliferation was 
assessed by detecting fluorescence at 590 nm.
Cilia formation
The formation of cellular cilia was assessed via 
confocal laser scanning microscopy imaging of cellular 
samples labeled for alpha-tubulin-acetylation using the 
mouse anti-acetylated alpha-tubulin (Abcam Ab24610) 
as primary mAb followed by secondary labeling with 
Alexa-488 conjugated anti-mouse antibody, and counter-
stained with DAPI for nuclear evaluation and cell count. 
Independent biological replicates of 72-h Dox treated 
control HT-29 and ZF-transduced cell lines were observed 
acquiring at least 5 field-of-view at lower magnification 
(40x, NA 1.40) and 3 field-of-view at higher magnification 
(63x, NA 1.40, zoomed 2x) using a SP5 true confocal laser 
scanning microscopy (Leica microsystems), accounting 
for n=650 analyzed cells. Z-volumes of around 15 
µm were acquired to have a complete 3D rendering of 
cellular samples. 16-bit images at 2048x2048 pixel rate 
were acquired for each Z-frame. For surface level cilia 
formation, analysis was specifically performed at surface 
Z-planes, evaluating the number of surface cilia per area 
and the density of cilia labeling (MFI/area). In parallel, 
the biological replicates were also acquired using a high-
resolution wide field microscope (Nikon Instruments), 
equipped with cSMOS camera (ANDOR) for larger field 
of view analysis at surface level (8400x7500 pixel, 16-bit). 
Analysis were performed using NIS-elements 4.51 (Nikon 
Instruments) and FIJI [38].
Statistical analysis
Statistical analysis of the phenotypic data was 
performed using two-tailed Student’s t-test. The statistical 
association between the clinico-pathological variables and 
TCTN2 IHC staining was analyzed using the two-tailed 
χ2 test and Fisher’s exact tests. For microscopy analysis, 
normally distributed data were assessed with ANOVA test 
followed by Dunnet comparisons. P- values ≤ 0.05 were 
considered significant. Statistical analysis was carried out 
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with the use of GraphPad software. The AUC (Area Under 
the Curve), SE, SP and optimal cutoff were obtained by 
the CombiROC prediction tool [39].
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